SAB Bio develops disease-modifying therapies for people impacted by type 1 diabetes.

SAB Bio

A clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D)

National Institutes of Health

U.S. Department of Defense

JDRF T1D Fund

BVF Partners

Commodore Capital

Marshall Wace

RA Capital Management

RTW Investments

Sessa Capital

T. Denny Sanford

South Dakota Equity Partners

Merck

Sioux Falls Development Foundation

SAB BIO

We are excited to announce we have evolved our name and visual identity! 

This is an important milestone, reflecting our strategic evolution and focus on addressing serious unmet needs in #type1diabetes. We look forward to showcasing our new branding during our poster presentation at the American Diabetes Association  84th Scientific Sessions on June 21-24, 2024 in Orlando, Florida and hope to see you there!

Read more about this announcement and check out our website at sab.bio.

#t1d #type1diabetes #diabetes #ADASciSessions

We are pleased to welcome @Lucy To as our newly appointed CFO, effective August 12. 

Lucy joins SAB with more than 18 years of investment banking and strategic operational expertise to SAB and will lead corporate finance, corporate strategy and approach to broader strategic business relationships at the company.

Read more about her joining SAB in the release found here: https://lnkd.in/dkHPUyH2

SAB was featured in the latest publication of Refresh Miami - link below!

What an incredible week we've had attending American Diabetes Association #adascisessions and meeting reknowned #type1diabetes advocates, researchers and thought leaders. 

Attending SAB BIO representatives included our Chairman and CEO Samuel Reich, our Co-Founder and President Eddie J Sullivan, EVP and COO Christoph Bausch, VP of Clinical Operations Angela Parizek, VP of Clinical Development Stan Stoyanov MD, MBA, and Senior Program Manager Eric Sandhurst, PhD. 

We look forward to continuing to build relationships with the other attendees we met. See you next year!

We are pleased to note our upcoming poster presentation at this week's American Diabetes Association #scientificsessions in Orlando on Sunday, June 23 for #ADA2024. 

Details about where to find our poster and connect with the presenter can be found below. 

https://lnkd.in/eX58xMxh

We've met so many incredible #type1diabetes advocates during the American Diabetes Association #ADAscisessions, and today SAB Senior Program Manager Eric Sandhurst, PhD presented in the Poster Hall and took questions. Also pictured below is our COO & EVP, Christoph Bausch. 

We'll be here one more day in the Poster Hall at 885-P if you'd like to check out our presentation. Come say hello!

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

SAB Biotherapeutics, Inc.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Aug 5, 2024 5:02 PM	0afe5153
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Aug 6, 2024 12:32 AM	1964412d
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Aug 5, 2024 5:02 PM	0d6af9f7
translate crunchbase fundingrounds	general
peers	general	Aug 5, 2024 5:02 PM	18bb1cd1
news basic	general	Aug 5, 2024 5:02 PM	b45f664e
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

BIO:SAB

SAB Bio

Last Close

4.13

05/11 21:00

Market Cap

29.53M

Beta: -

Volume Today

60.47K

Avg: -